VEGFA and gastric cancer: Using a novel proprietary assay, Jayson et al. 26,27 have reported that a VEGF-A assay that preferentially binds small VEGF-A isoforms may predict for benefit from bevacizumab in metastatic breast, pancreatic, and gastric cancers.